Clinical Trial Update: A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment [Phase 2]

View source ↗

Summary

Phase 2 study of TMC435 (telaprevir) with pegylated interferon alfa-2a and ribavirin in genotype 1 hepatitis C patients who never received treatment; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)
• TMC435 (telaprevir) (telaprevir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-06-16